石井 祐次(いしい ゆうじ) | データ更新日:2024.04.19 |
准教授 /
薬学研究院
臨床薬学部門
生命薬学
1. | 石井 祐次, 内外環境の撹乱による次世代影響ーダイオキシン研究を中心としてー, 九州大学環境報告書, Chapter_2-1, 2023.10, [URL]. |
2. | 古江 増隆, 石井 祐次, 月森 清己, 辻学, Aryl hydrocarbon receptor からみた油症の病態と治療開発 2020, 福岡医学雑誌, 112(2): 61-89 (2021), 2021.06. |
3. | Yuu Miyauchi, Shinji Takechi and Yuji Ishii, Functional interaction between cytochrome P450 and UDP-glucuronosyltransferase on the endoplasmic reticulum membrane: one of post-translational factors which possibly contributes to their inter-individual differences, Biological & Pharmaceutical Bulletin, https://doi.org/10.1248/bpb.b21-00286, 44(11): 1635-1644 (2021), 2021.11. |
4. | Frue Masutaka, ISHII YUJI, Tsukimori Kiyomi, Tsuji Gaku, Aryl Hydrocarbon Receptor and Dioxin-Related Health Hazards-Lessons from Yusho., Int J Mol Sci, doi: 10.3390/ijms22020708., 22(2):E708, 2021.01. |
5. | Amit V. Pandey, Colin J. Henderson, Yuji Ishii, Michel Kranendonk, Wayne L. Backes, Ulrich M. Zanger, Editorial Role of protein-protein interactions in metabolism: Genetics, structure, function, Frontiers in Pharmacology, 10.3389/fphar.2017.00881, 2017.11, [URL]. |
6. | YUJI ISHII, Memorial address for Dr. Hideyuki Yamada, distinguished professor, Drug Metabolism Reviews, 48(4): 471-472 (2016), 2016.08, [URL]. |
7. | Kenichiro Ogura, YUJI ISHII, Significance of non-cytochrome P450 (non-P450) enzymes in basic science, clinical field and drug development, Drug Metabolism and Pharmacokinetics, Volume 30, Issue 1, February 2015, Pages 1–2, 2015.02, [URL]. |
8. | ISHII YUJI, Arief Nurrochmad, Yamada, H., Modulation of UDP-glucuronosyltransferase activity by endogenous compounds, Drug Metabolism and Pharmacokinetics, 2010.04, [URL]. |
9. | ISHII YUJI, Shuso Takeda, Yamada, H., Modulation of UDP-glucuronosyltransferase activity by protein-protein association, Drug Metabolism Reviews, 2010.01, [URL]. |
10. | Yamada H, Ishii Y, Yamamoto M, Oguri K, Induction of the Hepatic Cytochrome P450 2B Subfamily by Xenobiotics: Research History, Evolutionary Aspect, Relation to Tumorigenesis, and Mechanism., Current Drug Metabolism, 7: 397 - 409., 2006.05. |
11. | 石井祐次, 石田卓巳, 武藤純平, 山田英之, 小栗一太, ダイオキシン類の毒性を安全に軽減できる化合物の候補:油症治療を目指した検討., 福岡医学雑誌, 96: 204 - 213., 2005.05. |
12. | Ishida T, Hori M, Ishii Y, Oguri K, Yamada H, Effects of dioxins on stress-responsive system and their relevance to toxicity., Journal of Dermatological Science, S1: S105 - S112 (2005)., 2005.05. |
13. | Yamada H, Ishii Y, Oguri K, Metabolism of Drugs of Abuse: Its Contribution to the Toxicity and the Inter-Individual Differences in Drug Sensitivity, Journal of Health Science, 51: 1-7., 2005.02. |
14. | Ishii Y, Takeda S, Yamada H, Oguri K, Functional protein-protein interaction of drug metabolizing enzymes, Frontiers in Bioscience, 10: 887-895., 2005.01. |
15. | Wells PG, Mackenzie PI, Roy Chowdhury J, Guillemette C, Gregory PA, Ishii Y, Hansen AJ, Kessler FK, Kim PM, Roy Chowdhury N, Ritter JK, Glucuronidation and the UDP-glucuronosyltransferases in health and disease, Drug Metabolism and Disposition, 32(3): 281-290., 2004.03. |
16. | Yuji Ishii, Kazuta Oguri, Liver proteins that are sensitive to a dioxin-like toxic compound, conplanar polychlorinated biphenyl, 3, 3', 4, 4', 5-pentachlorobiphenyl, Journal of Health Science, 48(4): 97-105, 2002.04. |
本データベースの内容を無断転載することを禁止します。